Press Releases

Alcyone Lifesciences and DNAtrix Enter Clinical Collaboration for Brain Cancer

Posted on May 20, 2015

Collaboration Combines Companies’ Expertise in Oncolytic Virus Therapy and Targeted Drug Delivery Lowell, MA and Houston, TX – May 19, 2015. Alcyone Lifesciences, Inc., a leader in neural intervention systems.. read more

DNATRIX COMPLETES $20 MILLION SERIES B FINANCING

Posted on October 14, 2014

San Diego, Calif.  –October 14, 2014 – DNAtrix, a clinical-stage oncolytic immunotherapy company, announced that it has completed a $20M Series B equity financing.  New investor Morningside Ventures led the.. read more

FDA GRANTS ORPHAN DRUG DESIGNATION TO DNATRIX’S DNX-2401 FOR THE TREATMENT OF MALIGNANT GLIOMA

Posted on October 7, 2014

SAN DIEGO, CA. – October 7, 2014 – DNAtrix, Inc., experts in oncolytic virus development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation.. read more

DNATRIX ANNOUNCES TREATMENT OF FIRST PATIENT WITH DNX-2401 IN RECURRENT GLIOBLASTOMA TRIAL

Posted on September 16, 2014

HOUSTON, TX. – September 15, 2014 – DNAtrix, Inc., experts in oncolytic virus development, today announced that the first patient was treated with the company’s lead product, DNX-2401, a replication.. read more

FDA GRANTS FAST TRACK STATUS TO DNATRIX DRUG DNX-2401 FOR RECURRENT GLIOBLASTOMA

Posted on June 17, 2014

SAN DIEGO, CA. – June 17, 2014 – DNAtrix, Inc., experts in oncolytic virus development, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status.. read more